ESPR - Esperion Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734-887-3903
http://www.esperion.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy M. Mayleben M.B.A.Pres, CEO & Director1.16M324.53k1961
Mr. Richard B. BartramCFO & Corp. Sec.429.25k1.12M1982
Mr. Mark A. GlickmanChief Commercial Officer629.14kN/A1966
Mr. Alexander Duke SchwartzSr. Director of Investor RelationsN/AN/AN/A
Ms. Regina Gore CavaliereChief Ethics & Compliance OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.